Stem cell and Cancer stem cell Regulation

Organisational unit: Research group



Many cancer patients are treated with chemotherapy that unspecifically targets all proliferative cells leading to severe side effects and a high relapse rate. The high relapse rate is a result of the inefficiency of conventional therapy to eradicate the cancer stem cells (CSC) that are believed to drive the disease and to be resistant to chemotherapy. Our goal is to understand the mechanisms driving cancer by functionally and molecularly identifying the cancer stem cells that are resistant to chemotherapy. In addition, we aim to develop a small molecule platform for drug profiling in order to find the most optimal drug combination for each patient targeting all cancer cells including the cancer stem cells. Our hope is that our results will improve survival and patient suffering during treatment, which will also have a positive effect on the socio-economic level.

Recent research outputs

Komorowska, K., Alexander Doyle, Martin Wahlestedt, Agatheeswaran Subramaniam, Debnath, S., Chen, J., Shamit Soneji, Van Handel, B., Mikkola, H. K. A., Kenichi Miharada, David Bryder, Jonas Larsson & Mattias Magnusson, 2017 Dec 19, In : Cell Reports. 21, 12, p. 3514-3523 10 p.

Research output: Contribution to journalArticle

Martin Wahlestedt, Ladopoulos, V., Isabel Hidalgo, Sanchez Castillo, M., Hannah, R., Petter Säwén, Haixia Wan, Monika Dudenhöffer-Pfeifer, Mattias Magnusson, Norddahl, G. L., Göttgens, B. & David Bryder, 2017 Nov 21, In : Cell Reports. 21, 8, p. 2251-2263 13 p.

Research output: Contribution to journalArticle

View All (4)